Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-08-09
1993-01-05
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514399, 514471, A61K 3134, A61K 3144, A61K 31415
Patent
active
051770814
ABSTRACT:
Persons suffering from negative symptoms of schizophrenia can be successfully treated using a histamine H.sub.2 -antagonist which crosses the blood-brain barrier so as to interact with histamine-H.sub.2 receptors in the brain. A preferred H.sub.2 -antagonist is famotidine. The H.sub.2 -antagonist may be used alone in patients who are relatively free of positive symptoms or it may be used in combination with known neuroleptics. A pharmaceutical composition containing both an H.sub.2 -antagonist and a neuroleptic is part of the present invention.
REFERENCES:
Chem. Abst. 103-52159y (1985).
Chem. Abst. 110-107925x (1989).
Chem. Abst. 104-28834q (1986).
Kaminski et al., Effect of famotidine on deficit symptoms of schizophrenia he Lancet, (1990) vol. 335, pp. 1351-1352.
Pickar et al., Neurochemical and Neural Mechanisms . . . Mod. Probl. Pharmacopsychiatry. Basel, (1990) vol. 24. pp. 124-151.
Morrison et al., Positive and Negative Symptoms in Schizophrenia The Journal of Nervous and Mental Disease, (1990) vol. 178, No. 6 pp. 377-384.
Carpenter et al., Deficit and Nondeficit Forms of Schizophrenia . . . Am. J. Psychiatry, (1988) vol. 145, No. 5 pp. 578-583.
Wyatt et al, Schizophrenia, just the facts . . . Schizophrenia Research, (1988) vol. 1 pp. 3-18.
Mesulam, Schizophrenia and the Brain The New England Journal of Medicine, (1990) vol. 322, No. 12 pp. 842-844.
Schwartz et al., Properties and Roles of the Three Subclasses of Histamine . . . J. exp. Biol., printed in Great Britain, (1986) vol. 124, pp. 203-224.
Itoh et al., Effects of Nociceptive Stimuli on Brain Histamine Dynamics Japan, J. Pharmacol. (1989) vol. 49, pp. 449-454.
Gogas et al., Inhibition of Naloxone-Resistant Antinociception . . . The Journal of Pharmacology and Experimental Therapeutics, (1989) vol. 248, No. 1.
Hough et al., A Role for Histamine and Histamine H.sub.2 -Receptors . . . Life Sciences, (1985) vol. 36, pp. 859-866.
Prell, Ann. Rev. Neurosci (1986) vol. 9, pp. 209-254.
Heleniak et al., Histamine Methylation in Schizophrenia Medical Hypotheses, (1989) vol. 30, pp. 167-174.
Heleniak et al., Histamine and Prostaglandins in Schizophrenia Journal of Orthomolecular Psychiatry, vol. 14, No. 3, pp. 162-177.
Lucca et al., Biochemical Investigation of Histidinemia . . . Bil. Psychiatry, (1990) vol. 27, pp. 69-75.
Hough, Cellular Localization and Possible Functions for Brain Histamine . . . Progress in Neurobiology, (1988) vol. 30, pp. 469-505.
White et al., Behavioural effects of histamine and its antagonists: a review Psychopharmacology, (1988) vol. 95, pp. 1-14.
Emsley et al., Water Excretion and Plasma Vasopressin in Psychotic Disorders Am. J. Psychiatry (1989) vol. 146, No. 2, pp. 250-253.
Specht et al., Histamine-Elicted Drinking in Weanling and Adult Rats Physiology & Behavior, (1989) vol. 45, pp. 63-70.
Koczapski et al., Individual Differences in Serum Sodium Level . . . Am. J. Psychiatry, (1989) vol. 146, No. 12 pp. 1614-1615.
USP DI, (1990) Histamine H.sub.2 -Receptor Antagonists (systemic) pp. 11496-1505.
Gelenberg, Famotidine for Schizophrenia?--Biological Therapies in Psychiatry (Newsletter) (1990) vol. 13, No. 11 pp. 41 and 44.
Friedman S. J.
The Mount Sinai School of Medicine of the City University of New
LandOfFree
Method and pharmaceutical composition for the treatment of schiz does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and pharmaceutical composition for the treatment of schiz, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and pharmaceutical composition for the treatment of schiz will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2390709